Malignant Melanoma | Access and Reimbursement | EU5 | 2017

The malignant melanoma market in Europe has become crowded. Small-molecule targeted therapies such as Novartis’s Tafinlar and Mekinist, monoclonal antibodies including Merck & Co.’s Keytruda and Bristol-Myers Squibb’s Opdivo, and Amgen’s therapeutic vaccine Imygic have all been approved in the last six years. The premium price of these agents has resulted in spiraling healthcare costs, which means payers must make increasingly economical reimbursement decisions. In turn, oncologists face mounting challenges as they strive to balance superior efficacy and clinical need with strict eligibility criteria and other prescribing restrictions set by healthcare agencies. This research examines the reimbursement environment for malignant melanoma in the EU5, and analyzes the evolving impact of payer policy on prescribing as additional costly therapies penetrate the market and healthcare budgets tighten.

Questions Answered

  • What role do key brands play in the treatment of malignant melanoma in the EU5? In what treatment settings are they mostly prescribed? How is their use restricted in each country under study?
  • Do EU5 payers believe that efficacy of the various therapy combinations justifies their cost, and which drug or drug combination do they think performs best on clinical and other attributes?
  • How do oncologists and payers view therapies in late-stage development for malignant melanoma? How will these agents perform in HTA, and what pricing and reimbursement terms can they expect to achieve?
  • How will prescribing evolve, and what factors will drive key changes?

Product Description

Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Login to access report